Lenvika (Lenvatinib, E7080) is a tyrosine kinase inhibitor. Lenvika (Lenvatinib, E7080) inhibits kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib is indicated for the treatment of Hepatocellular carcinoma (HCC), Differentiated thyroid cancer (DTC), Advanced renal cell carcinoma (RCC), and Advanced endometrial carcinoma (EC). Lenvika, a generic Lenvatinib (Lenvima, E7080) manufactured by Genvio Pharma Limited. Genvio Pharma Limited is one of the top anticancer medicine manufacturer in Bangladesh. Lenvika is the brand of Lenvatinib (E7080) at an affordable price compared to the cost of Lenvima manufactured by Eisai
|Product Name||LENVIKA 4|
|Generic Name||Lenvatinib Mesylate INN 4mg Capsule|
|FDA Approved Indications||Lenvatinib is indicated for the treatment of
First-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).
In combination with Everolimus, Lenvatinib is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy.
In combination with Pembrolizumab, Lenvatinib is indicated for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.
|Packaging||Each commercial box contains 3×10’s capsules in Alu-Alu blister pack.|
|Prescribing Information||LENVIKA 4 (PDF)|